The Ligandable Human Proteome

WD repeat-containing protein 5

Index	Ligand Name	Structure	PDB code	ligand desolvation
1	ia9	Crystal structure of human WD REPEAT DOMAIN 5 in complex with 2-chloro-4-fluoro-3-methyl-N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]benzamide	4ia9	90
2	g2v	Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design	6dai	88.31
3	0bw	Crystal structure of human WD repeat domain 5 with compound	3ur4	88.05
4	5mo	Crystal structure of human WDR5 in complex with compound 9e	5eap	87.54
5	hlj	Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity	6e23	86.06
6	np7	Crystal structure of human WD repeat domain 5 with compound	3smr	84.74
7	5mq	Crystal structure of human WDR5 in complex with compound 9d	5ear	84.46
8	5ml	Crystal structure of human WDR5 in complex with compound 9h	5eal	84.04
9	hlm	Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design	6e1y	82.26
10	g2d	Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design	6das	81.78
11	hh7	WDR5 in complex with a WIN site inhibitor	6dy7	81.13
12	g1y	Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design	6dak	77.46
13	hhm	WDR5 in complex with a WIN site inhibitor	6dya	76.55
14	g2j	Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design	6dar	75.76
15	hls	Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity	6e22	74.97
16	35q	Crystal structure of human WDR5 in complex with compound OICR-9429	4ql1	71.99